Author: jameshebrew

It is also worth highlighting that capital investments worth over USD 17 billion have been made by various private and public sector investors during the last five years to fund... Read More

Over time, both drug developers and medical device Injectors manufacturers, have entered into strategic alliances to combine their respective expertise and develop appropriate drug-device combination products. Presently, multiple such combinations,... Read More

The growing popularity of ADCs is evident from the number of patents filed / granted for ADCs, which has increased from 1,992 in 2011 to over 22,700 in the first... Read More

The growing popularity of ADCs is evident from the number of patents filed / granted for ADCs, which has increased from 1,992 in 2011 to over 22,700 in the first... Read More

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. What is the objective of the collaboration: The partnership will... Read More

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements.Considering the... Read More

On October 31, 2019, Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1/2 study (NCT04145622) evaluating DS-7300. What is DS-7300: DS-7300... Read More

Over the years, several cancer-related biomarkers have been identified, which can be used to predict response to certain types of immunotherapy drugs. However, due to the inherent complexity of the... Read More

Talaris Therapeutics, a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY, announced the initiation of FREEDOM-1 (NCT03995901), the company’s Phase 3 clinical trial of FCR001 in living... Read More

Orchard Therapeutics, a commercial-stage biopharmaceutical company, announced initial results from a clinical trial (NCT03392987) with a cryopreserved formulation of OTL-200, gene therapy in development for the treatment of metachromatic leukodystrophy... Read More